Business Description
Celadon Pharmaceuticals PLC
ISIN : GB00BDQYGP38
Description
Celadon Pharmaceuticals PLC focuses on growing indoor hydroponic high-quality cannabis initially for use within the chronic pain market. It has two reportable segments Celadon is a Build of grow facilities, growing medical grade cannabis and research in the GMP lab, and Harley Street (CPC) is a clinical study into the pain relief benefits of medicinal cannabis.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.35 | |||||
| Equity-to-Asset | 0.32 | |||||
| Debt-to-Equity | 1.54 | |||||
| Debt-to-EBITDA | -1.02 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | -0.33 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 87.21 | |||||
| 9-Day RSI | 78.63 | |||||
| 14-Day RSI | 71.52 | |||||
| 6-1 Month Momentum % | -4.41 | |||||
| 12-1 Month Momentum % | -40.91 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.86 | |||||
| Quick Ratio | 1.84 | |||||
| Cash Ratio | 1.15 | |||||
| Days Inventory | 78.66 | |||||
| Days Sales Outstanding | 14850.94 | |||||
| Days Payable | 3696.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -0.04 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -383.33 | |||||
| Operating Margin % | -35566.67 | |||||
| Net Margin % | -38891.67 | |||||
| FCF Margin % | -34791.67 | |||||
| ROE % | -110.69 | |||||
| ROA % | -61.66 | |||||
| ROIC % | -95.25 | |||||
| ROC (Joel Greenblatt) % | -85.67 | |||||
| ROCE % | -43.85 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 20.98 | |||||
| Price-to-Tangible-Book | 23.5 | |||||
| EV-to-EBIT | -13.26 | |||||
| EV-to-EBITDA | -14.85 | |||||
| EV-to-Revenue | 3291.37 | |||||
| EV-to-FCF | -7.73 | |||||
| Earnings Yield (Greenblatt) % | -7.54 | |||||
| FCF Yield % | -11.07 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Celadon Pharmaceuticals PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.024 | ||
| EPS (TTM) (€) | -0.132 | ||
| Beta | 0 | ||
| Volatility % | 196.09 | ||
| 14-Day RSI | 71.52 | ||
| 14-Day ATR (€) | 0.096123 | ||
| 20-Day SMA (€) | 0.9259 | ||
| 12-1 Month Momentum % | -40.91 | ||
| 52-Week Range (€) | 0.73437 - 1.8 | ||
| Shares Outstanding (Mil) | 64.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Celadon Pharmaceuticals PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Celadon Pharmaceuticals PLC Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Celadon Pharmaceuticals PLC Frequently Asked Questions
What is Celadon Pharmaceuticals PLC(LSE:CEL)'s stock price today?
The current price of LSE:CEL is €1.18. The 52 week high of LSE:CEL is €1.80 and 52 week low is €0.73.
When is next earnings date of Celadon Pharmaceuticals PLC(LSE:CEL)?
The next earnings date of Celadon Pharmaceuticals PLC(LSE:CEL) is 2024-06-05 Est..
Does Celadon Pharmaceuticals PLC(LSE:CEL) pay dividends? If so, how much?
Celadon Pharmaceuticals PLC(LSE:CEL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers